IDEAYA Biosciences, Inc., an oncology-focused precision medicine company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's product candidate in clinical development is IDE196, a protein kinase C inhibitor for genetically-defined cancers having GNAQ or GNA11 gene mutations. Its preclinical pipeline includes various synthetic lethality programs targeting MAT2A in tumor cells having MTAP gene deletions; Pol-theta in tumors with genetic mutations in homologous recombination deficiency, including BRCA mutations; PARG in tumors with genetic mutations in base excision repair; and WRN in high microsatellite instability tumors. The company was founded in 2015 and is headquartered in South San Francisco, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone650-443-6209
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees56
Next Earnings Date2/12/2020 (Estimated)
OptionableNot Optionable
IDEAYA Biosciences (NASDAQ:IDYA) Frequently Asked Questions
What is IDEAYA Biosciences' stock symbol?
IDEAYA Biosciences trades on the NASDAQ under the ticker symbol "IDYA."
How were IDEAYA Biosciences' earnings last quarter?
IDEAYA Biosciences (NASDAQ:IDYA) issued its quarterly earnings results on Wednesday, November, 13th. The company reported ($0.54) EPS for the quarter, beating the consensus estimate of ($0.66) by $0.12. View IDEAYA Biosciences' Earnings History.
When is IDEAYA Biosciences' next earnings date?
What price target have analysts set for IDYA?
5 brokerages have issued 12-month target prices for IDEAYA Biosciences' shares. Their forecasts range from $14.00 to $30.00. On average, they expect IDEAYA Biosciences' share price to reach $19.20 in the next year. This suggests a possible upside of 91.4% from the stock's current price. View Analyst Price Targets for IDEAYA Biosciences.
What is the consensus analysts' recommendation for IDEAYA Biosciences?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IDEAYA Biosciences in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for IDEAYA Biosciences.
Has IDEAYA Biosciences been receiving favorable news coverage?
News articles about IDYA stock have trended very negative this week, InfoTrie Sentiment reports. The research group identifies negative and positive news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. IDEAYA Biosciences earned a news sentiment score of -3.0 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the stock's share price in the near future. View News Stories for IDEAYA Biosciences.
Are investors shorting IDEAYA Biosciences?
IDEAYA Biosciences saw a increase in short interest in the month of December. As of December 31st, there was short interest totalling 87,300 shares, an increase of 15.9% from the December 15th total of 75,300 shares. Based on an average daily volume of 51,800 shares, the days-to-cover ratio is presently 1.7 days. Currently, 0.9% of the company's stock are sold short. View IDEAYA Biosciences' Current Options Chain.
Who are some of IDEAYA Biosciences' key competitors?
Some companies that are related to IDEAYA Biosciences include Eagle Pharmaceuticals (EGRX), Dova Pharmaceuticals (DOVA), Collegium Pharmaceutical (COLL), Homology Medicines (FIXX), Stoke Therapeutics (STOK), Frequency Therapeutics (FREQ), CannTrust (CNTTF), Provention Bio (PRVB), Cytokinetics (CYTK), ANI Pharmaceuticals (ANIP), Omeros (OMER), Urogen Pharma (URGN), ImmunoGen (IMGN), Retrophin (RTRX) and Basilea Pharmaceutica (BPMUF).
What other stocks do shareholders of IDEAYA Biosciences own?
Who are IDEAYA Biosciences' key executives?
IDEAYA Biosciences' management team includes the folowing people:
- Mr. Yujiro S. Hata, Co-Founder, CEO, Pres & Director (Age 45)
- Mr. Jeffrey Hager, Sr. VP, CTO, Head of Target Discovery & External Innovation (Age 55)
- Mr. Paul A. Stone, Sr. VP, Gen. Counsel & Head of Operations (Age 55)
- Mr. Michael P. Dillon, Sr. VP, Chief Scientific Officer & Head of Research (Age 52)
- Dr. Julie Hambleton, Sr. VP, Chief Medical Officer & Head of Devel. (Age 61)
When did IDEAYA Biosciences IPO?
(IDYA) raised $70 million in an IPO on Thursday, May 23rd 2019. The company issued 5,000,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan, Citigroup and Jefferies acted as the underwriters for the IPO.
How do I buy shares of IDEAYA Biosciences?
Shares of IDYA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is IDEAYA Biosciences' stock price today?
One share of IDYA stock can currently be purchased for approximately $10.03.
How big of a company is IDEAYA Biosciences?
What is IDEAYA Biosciences' official website?
How can I contact IDEAYA Biosciences?
IDEAYA Biosciences' mailing address is 7000 SHORELINE COURT SUITE 350, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-443-6209 or via email at [email protected]
MarketBeat Community Rating for IDEAYA Biosciences (NASDAQ IDYA)
MarketBeat's community ratings are surveys of what our community members think about IDEAYA Biosciences and other stocks. Vote "Outperform" if you believe IDYA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IDYA will underperform the S&P 500 over the long term. You may vote once every thirty days.
